Wehnert J, Sage S
Klinik für Urologie, Medizinischen Akademie Carl Gustav Carus, Dresden.
Z Urol Nephrol. 1989 May;82(5):259-63.
46 patients suffering from urgency/urge incontinency were treated with Mictonorm and Spasuret in a crossing-over study. In consideration of the placebo effect in this disease both agents were tested versus a non-verum. The application period was 4 weeks and the dosage was 45 mg/d Mictonorm and 300 mg/d Spasuret, respectively. Both with Mictonorm and with Spasuret a significant reduction of micturition frequency and an increase of the compliance could be observed, whereas the placebo was ineffective. A markedly growth of the maximal bladder capacity (16.9%) was obtained only by Mictonorm. Both agents keep likewise to an improvement of the symptoms or urgency/urge incontinency. Side effects could observed in a small size without a breaking-off of the treatment.
在一项交叉研究中,对46名患有尿急/急迫性尿失禁的患者使用米多君和司帕沙星进行治疗。考虑到该疾病中的安慰剂效应,两种药物均与非真实对照物进行测试。应用期为4周,剂量分别为米多君45毫克/天和司帕沙星300毫克/天。使用米多君和司帕沙星均可观察到排尿频率显著降低且顺应性增加,而安慰剂无效。仅米多君可使最大膀胱容量显著增加(16.9%)。两种药物同样能改善尿急/急迫性尿失禁症状。可观察到轻微的副作用,但未导致治疗中断。